Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-01-08
2000-01-04
Kemmerer, Elizabeth
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 530350, 530351, 530395, 530397, 530399, 436501, C07K 1400, A61K 3816
Patent
active
060110023
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to the production and use of circularly permuted ligands and chimeric proteins formed by the joining of two or more proteins where one of the proteins is circularly permuted. The chimeric proteins may be fusion proteins.
BACKGROUND OF THE INVENTION
In a chimeric molecule, two or more molecules that exist separately in their native state are joined together to form a single molecule having the desired functionality of all of its constituent molecules. The constituent molecules of a chimeric molecule may be joined by chemical conjugation or, where the constituent molecules are all polypeptides, they may be fused together to form a single continuous polypeptide. If one of the constituent molecules is a ligand, then the resulting chimeric molecules bind to cells bearing receptors specific for the particular ligand.
Where the first constituent molecule is a ligand and the second protein is a cytotoxin, the chimeric molecule may act as a potent cell-killing agent specifically targeting the cytotoxin to cells bearing a particular receptor type. For example, chimeric fusion proteins which include interleukin 4 (IL4) or transforming growth factor (TGF.alpha.) fused to Pseudomonas exotoxin (PE) or interleukin 2 (IL2) fused to Diphtheria toxin (DT) have been tested for their ability to specifically target and kill cancer cells (Pastan et al., Ann. Rev. Biochem., 61: 331-354 (1992)).
Alternatively, where the ligand is attached to another specific binding moiety such as an antibody, a growth factor, or another ligand, the chimeric molecule may act as a highly specific bifunctional ligand. This ligand may act to bind and enhance the interaction between cells or cellular components to which the chimeric molecule binds. Thus, for example, where the chimeric molecule is a fusion protein in which a growth factor is fused to an antibody or antibody fragment (e.g. an Fv fragment of an antibody), the antibody may specifically bind antigen positive cancer cells while the growth factor binds receptors (e.g., IL2 or IL4 receptors) on the surface of immune cells. The fusion protein may thus act to enhance and direct an immune response toward target cancer cells.
Ligands are typically employed in chimeric molecules to act as specific targeting moieties. Generally it is desirable to increase specificity and affinity and decrease cross-reactivity of the chimeric molecule to make it more effective. For example, native PE and DT are highly toxic compounds that typically bring about death through liver toxicity. PE and DT can be transformed into chimeric toxins by removing the native targeting component of the toxin and replacing it with a different specific targeting moiety (e.g. IL4 which targets cells bearing IL4 receptors). However, even these chimeric toxins show some non-specific binding. They attack the liver in addition to their target cells and, when given in large doses, may also produce death due to liver toxicity.
It has been observed that growth factors, and other targeting moieties, frequently show lower specificity and affinity for their targets when they are incorporated into chimeric molecules such as fusion proteins. See, for example, Debinski, et al., J. Biol. Chem., 268: 14065-14070 (1993); Lorberboum-Galski, et al., J. Biol. Chem., 263: 18650-18656 (1988); Williams, et al., J. Biol. Chem., 265: 11885-11889 (1990); and Edwards, et al. Mol. Cell. Biol., 9: 2860-2867 (1989).
SUMMARY OF THE INVENTION
This invention provides novel modified forms of ligands such as interleukin 4 (IL4) wherein the amino and carboxy ends are joined together, directly or through a linker, and new amino and carboxy terminal ends are formed al. a different location within the ligand. These modified ligands are as fully active as the original ligands. Since the modification of the ligand represents a rearrangement of the molecule, neither the function, nor the desirability of such molecules was apparent prior to the work described here. Such rearranged molecules are also referred to as circul
REFERENCES:
patent: 5635599 (1997-06-01), Pastan et al.
Curti. Crit. Rev. Oncology/Hematology 14:29-39, 1993.
Jain. Sci. Am. 271:58-65, 1994.
Buchwalder, et al., A fully active variant of dihydrofolate reductase with a circularly permuted sequence. Biochemistry, 31: 1621-1630 (1992).
Cunningham, et al., Favin versus concanavalin A: circularly permuted amino acid sequences. Proc. Natl. Acad. Sci. USA, 76: 3218-3222 (1979).
Goldenberg, et al. Circular and circularly permuted forms of bovine pancreatic trypsin inhibitor. J. Mol. Biol., 165: 407-413 (1983).
Goldenberg, Circularly permuted proteins. Protein Eng., 7: 493-495 (1989).
Hoppe, et al., Insulin analogues with permuted A chain N-terminus. Z. Physiol. Chem., 356: 981-986 (1975). (Abstract only).
Horlick, et al., Permuteins of interleukin 1.beta.--a simplified approach for the construction of permutated proteins having new termini. Protein Eng., 5: 427-431 (1992).
Luger, et al., Correct folding of circularly permuted variants of a .beta..alpha. barrel enzyme in vivo. Science, 243: 206-210 (1989).
Min, et al., Non-glycosylated recombinant pro-concanavalin A is active without polypeptide cleavage. E.M.B.O. J., 11: 1303-1307 (1992).
Pan, et al., Circularly permuted DNA, RNA and proteins--a review. Gene, 125:11-114 (1993).
Pastan, et al., 1992 Ann. Rev. Biochem. 61:331-54.
Ogata et al., 1989 PNAS USA 86:4215-9.
Puri et al., J. Cancer Res. 51:3011-.
Pastan et al., Science 254:1173-7.
Kreitman et al., PNAS USA 91:6889-93.
The Journal of Biological Chemistry, vol. 268, No. 19, Jul. 5, 1993 pp. 14065-14070, Waldemar Debinski et al. see page 14068, first paragraph of the Discussion.
Science, vol. 245, Sep. 29, 1989 pp. 1493-1496, Cynthia E. Dunbar et al., `Carboxyl-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth` see the whole document.
Cancer Research, vol. 55, No. 15, Aug. 1, 1995 pp. 3357-3363, Robert J. Kreitman et al., `Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma`.
Pan, et al., Circularly permuted DN
Kreitman Robert J.
Pastan Ira
Puri Raj K.
Kemmerer Elizabeth
The United States of America as represented by the Department of
LandOfFree
Circularly permuted ligands and circularly permuted chimeric mol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Circularly permuted ligands and circularly permuted chimeric mol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Circularly permuted ligands and circularly permuted chimeric mol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1072633